Paper Details

  1. Home
  2. Paper Details

Emerging drugs and combination strategies for basal cell carcinoma.

Author: DreierJil, DummerReinhard, FeldererLea, GobbiSharon, KunstfeldRainer, NägeliMirjam

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Smoothened inhibitors are a promising new treatment for basal cell carcinoma (BCC), but more long-term data are needed to understand their effectiveness and the optimal duration of treatment.
Paper Details　
Original Abstract of the Article :
Basal cell carcinoma (BCC) is a malignancy that is driven by an activated Hedgehog (Hh) pathway. Smoothened inhibitors are a new promising treatment option for patients with locally advanced or metastatic BCC or basal cell nevus syndrome. But long-term data are still limited, the optimal treatment d...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1517/14728214.2014.914171

データ提供：米国国立医学図書館（NLM）

New Treatments for Basal Cell Carcinoma: Smoothened Inhibitors and Combination Therapies

Basal cell carcinoma (BCC) is a [common skin cancer] that can be a persistent challenge for patients. This review explores [emerging drugs and combination strategies] for the treatment of BCC. The authors focus on [smoothened inhibitors], a promising new class of drugs targeting the Hedgehog (Hh) pathway, which is often activated in BCC. They acknowledge that [long-term data on smoothened inhibitors are still limited] and [acquired resistance] is a concern.

A New Era in BCC Treatment: Smoothened Inhibitors

The review highlights the potential of [smoothened inhibitors] as a [novel treatment option for locally advanced or metastatic BCC]. However, it also emphasizes the need for [further research to evaluate their long-term effectiveness and safety].

Staying Informed and Staying Ahead of BCC

Patients with BCC should stay informed about [new treatment options] and discuss them with their dermatologist. Understanding the risks and benefits of different therapies is crucial for making informed decisions about their care.

Dr.Camel's Conclusion

This review, like a desert explorer discovering a new oasis, introduces promising new avenues for treating BCC. Smoothened inhibitors represent a significant advancement in the fight against this common skin cancer, offering hope for a brighter future for patients.

Date :
  1. Date Completed 2015-03-30
  2. Date Revised 2016-11-25
Further Info :

Pubmed ID

24773312

DOI: Digital Object Identifier

10.1517/14728214.2014.914171

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.